A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

3533 Background: AT7519M is a structure-based rationally designed Nan molar small molecular Cyclin-dependent Kinase (CDK) inhibitor (CDK 1, 2, 4, 5). It has been evaluated in a first in human trial...